Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin in Children With Growth Hormone Deficiency

Next Previous
Trial Profile

A Trial Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin in Children With Growth Hormone Deficiency

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somapacitan (Primary) ; Somatropin
  • Indications Somatotropin deficiency
  • Focus Registrational; Therapeutic Use
  • Acronyms REAL4
  • Sponsors Novo Nordisk; Novo Nordisk Pharma

    • Most Recent Events

    • 21 Mar 2024 Results of subanalysis evaluating the efficacy and tolerability of somapacitan in Japanese children with GHD after 104 weeks of treatment and after switch from daily, published in the Clinical Endocrinology
    • 08 Dec 2023 Results investigating response prediction using pre-treatment transcriptome in children with GH deficiency (GHD) treated with once-weekly somapacitan, published in the Journal of Clinical Endocrinology and Metabolism
    • 05 Jul 2023 Results evaluating the efficacy and tolerability of somapacitan in children with GHD after 2 years of treatment and after switch from daily GH, published in the Journal of Clinical Endocrinology and Metabolism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top